Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Nassif

Adult Reconstructive Orthopaedic Surgery Cedar Rapids, IA Medical Doctor

NPI 1336147800 CMS profile 332814

202 10Th Street Se, Cedar Rapids, IA 52403

Open in the dashboard

General payments

$30,893

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,400 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Jeffrey Nassif of Cedar Rapids, IA is reported in the CMS Open Payments database as having received $30,893 across 78 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,400 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $650 12
2024 General $360 5
2023 General $487 5
2022 General $18,970 27
2021 General $4,519 7
2020 General $4,908 9
2019 General $998 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Nassif
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jeffrey Nassif were reported at $650. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Jeffrey Nassif Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $998 $1,416 $292–$9,336 $163
2020 $4,908 $647 $141–$6,474 $114
2021 $4,519 $1,073 $211–$6,497 $132
2022 $18,970 $1,217 $236–$6,299 $149
2023 $487 $1,082 $246–$6,818 $160
2024 $360 $1,575 $323–$8,944 $164
2025 $650 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $18,587 27 payments
  2. Maxx Orthopedics, Inc. $9,039 11 payments
  3. Zimmer Biomet Holdings, Inc. $1,883 19 payments
  4. Stryker Corporation $661 9 payments
  5. Smith+Nephew, Inc. $358 4 payments
  6. Arthrex, Inc. $148 1 payment
  7. Pacira CryoTech Incorporated $92 1 payment
  8. DePuy Synthes Sales Inc. $61 2 payments
  9. Vertex Pharmaceuticals Incorporated $28 2 payments
  10. SPR Therapeutics, Inc $22 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $16,040 5 payments
  2. Honoraria $7,540 1 payment
  3. Food and Beverage $4,264 63 payments
  4. Travel and Lodging $3,049 9 payments
Products named General payments · program years 2019–2025
  1. Exparel Pain Management $18,141 20 payments
  2. Zilretta $8,751 12 payments
  3. Freedom Total Knee System $5,039 10 payments
  4. ROSA $777 7 payments
  5. Iovera $333 5 payments
  6. JOURNEY II $175 2 payments
  7. EXPAREL Pain Management $156 2 payments
  8. GAMMA $154 2 payments
  9. REAL INTELLIGENCE $148 1 payment
  10. Comprehensive Shoulder System $133 1 payment
  11. Other $1,438 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,381

Median for Orthopedic Surgery: 203

Drug cost

$10,997

Median for Orthopedic Surgery: $1,433

Branded share of claims

7.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 17 $6,522
Oxycodone Hcl Generic 120 $617
Meloxicam Generic 356 $583
Carbidopa-Levodopa Carbidopa/Levodopa Brand 12 $512
Nabumetone Generic 46 $371
Tramadol Hcl Generic 157 $368
Amoxicillin Generic 305 $357
Clindamycin Hcl Generic 60 $344
Tamsulosin Hcl Generic 12 $303
Cephalexin Generic 87 $260

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$272,831

Of which drugs: $2,974

Medicare patients

488

Average age 74

Services billed

5,260

287 women, 201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 29%
Depression 28%
Diabetes 24%
Chronic kidney disease 23%
Heart failure 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 146 1,760 $1,269

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $32
$32 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record